A 3-Year Survival Update from a Phase 2 Study of Paclitaxel Plus Cisplatin and 5-Fuorouracil Induction Chemotherapy for Locally Advanced Borderline-Resectable Esophageal Squamous Cell Carcinoma: The NEOCRTEC-1601 Clinical Trial

CONCLUSION: Long-term follow-up evaluation confirmed that TPF followed by surgery is feasible and promising in terms of survival for BR-ESCC patients. Trial Registration ClinicalTrials.gov identifer: NCT02976909.PMID:37919448 | DOI:10.1245/s10434-023-14513-0

Source: Ann Oncol - November 3, 2023 Category: Cancer & Oncology Authors: Jia-Di Wu Zhi-Qiang Wang Qiao-Qiao Li Zhi-Chao Li Chao Ren De-Shen Wang Ji-Yang Chen Qiong Tan Yu-Hong Li Hong Yang Source Type: research